For scientists involved in pharmaceutical development, high throughput experimentation is commonplace for activities such as reaction optimization, process development, catalyst screening, and reaction scale-up. While there are many observed benefits of implementing HTE workflows in laboratories, it also dramatically affects corporate informatics infrastructures and there are significant impediments to its utilization. In order to optimize laboratory efficiency and support the lab of the future, the industry requires a technological solution that can help streamline workflows and demonstrate data integrity. That's why we've recently launched Katalyst D2D to solve the industry’s greatest pain points in HT experimentation. Read on to learn more about our new solution for high throughput experimentation and parallel synthesis.
Andrew Anderson muses about our upcoming visit to our 23rd Pittcon conference as we celebrate our 25th anniversary with an exciting new product launch.
In pharma, drug substances (and the resulting formulated drug products) must conform to a variety of quality specifications in order to be approved for use by healthcare practitioners and patients. While most of us who have worked in pharma know the various regulatory statutes and advisory guidance (and can quote them chapter and verse!), my belief is that there is a challenge in the practical and efficient implementation of quality practices that support conformance. When considering the increasing ‘fracturing’ of supply chains that support demand for drug substances in both clinical and healthcare systems worldwide, this challenge only continues to grow.
Andrew Anderson reports on the 2017 AAPS Annual Conference by taking a closer look at his recent byline in Laboratory Equipment. He also introduces Joe DiMartino, ACD/Labs' newly appointed solution manager for Luminata, and previews Joe's recent Q&A with Outsourcing-Pharma.com, which discusses how QbD and impurity control management directly impact process development within pharmaceutical R&D organizations.
PITTCON 2017 was a particularly big event for the ACD/Labs team this year because we were focused on the launch of Luminata, our new informatics solution for comprehensive impurity and characterization management. The five days we spent in Chicago were the culmination of months of hard work across the entire organization, and I’m pleased to say that the launch went off without a hitch. I had the opportunity to meet with the folks at LabTube to talk about ACD/Labs and our vision for Luminata. Watch the video in our post.
Earlier this year, I had a conversation with Sophia Ktori, a reporter for Scientific Computing World, to talk about security issues in the age of R&D outsourcing. In the ensuing article, Sophia stated, “The R&D sector is increasingly turning to collaborative, partnered and outsourced projects to boost innovation, reduce costs and help expedite development.” While this is not an industry secret, this trend has led to a number of security concerns in our industry, and after looking back, I feel our discussion still rings true almost 10 months later.
ACD/Labs is headed to Boston for the annual Bio-IT World Conference & Expo held at the Seaport World Trade Center from April 5th-7th. Over 3,000 life sciences, IT, and pharmaceutical professionals will gather in Beantown to discuss the emerging technologies and research that is transforming the industry. As the newest member of the team, rejoining ACD/Labs as Vice President of Business Development in December 2015, I’m ecstatic to be at this year’s conference alongside my colleagues Sanji Bhal, Graham McGibbon and Larry Brescio. Read more to find out what I’ll be up to at the show and where you can find the ACD/Labs team.
The 'Amazon Effect' describes how online shopping giant, Amazon, sorts data and matches similar products to one another—providing customers with a customized list of products they may be interested in. In laboratory informatics, scientists organize and analyze data in a very similar way. By using software like ACD/Spectrus Platform, scientists—from different laboratories using a variety of instruments—can combine and process their large data sets in a single interface that delivers quality results.
For those of you that know me, you may be wondering why I re-joined ACD/Labs; for those that don’t know me yet, let me give you some insight into my return. When I think back on many happy firsts in my life, and I can’t not think about my career experience at the same time. And when I began to contemplate a return to ACD/Labs, the first thing that came to my mind was, of all things, Star Wars and JJ Abrams. Let me explain...